Payment overview · 2025
General Payments
$339.37
19 reported records · 9 companies
Healthcare provider profile · identity verified
Melanie Wallace, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TUPELO, MS · NPI 1346207222
Verified facts
What the public records show
CMS Open Payments records show Melanie Wallace, M.D. received $339.37 in general payments during 2025 across 19 reported records.
Lilly USA, LLC accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.31 | 36.3% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.47 | 14.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.72 | 10.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.30 | 9.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.47 | 8.7% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $25.54 | 7.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.09 | 4.7% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $15.51 | 4.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.96 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.37 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $123.31 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.97 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.47 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $29.47 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 587 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 537 | 135 |
| Losartan Potassium | Losartan Potassium | 407 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 90 |
| Omeprazole | Omeprazole | 384 | 107 |
| Gabapentin | Gabapentin | 362 | 84 |
| Potassium Chloride | Potassium Chloride | 345 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 80 |
| Lisinopril | Lisinopril | 298 | 81 |
| Carvedilol | Carvedilol | 289 | 74 |
| Metformin Hcl | Metformin Hcl | 289 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 74 |
| Famotidine | Famotidine | 249 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 74 |
| Montelukast Sodium | Montelukast Sodium | 178 | 47 |
| Furosemide | Furosemide | 167 | 49 |
| Ezetimibe | Ezetimibe | 160 | 47 |
| Glimepiride | Glimepiride | 140 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 35 |
| Alendronate Sodium | Alendronate Sodium | 132 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 43 |
| Donepezil Hcl | Donepezil Hcl | 113 | 26 |
| Tramadol Hcl | Tramadol Hcl | 97 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 20 |
| Trazodone Hcl | Trazodone Hcl | 79 | 26 |
| Eliquis | Apixaban | 78 | 14 |
| Allopurinol | Allopurinol | 75 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 20 |
| Buspirone Hcl | Buspirone Hcl | 72 | 17 |
| Sertraline Hcl | Sertraline Hcl | 71 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 21 |
| Meclizine Hcl | Meclizine Hcl | 69 | 29 |
| Simvastatin | Simvastatin | 65 | 19 |
| Meloxicam | Meloxicam | 62 | 24 |
| Metformin Hcl Er | Metformin Hcl | 61 | 15 |
| Nystatin | Nystatin | 57 | 29 |
| Atenolol | Atenolol | 55 | 13 |
| Prednisone | Prednisone | 54 | 38 |
| Primidone | Primidone | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Spironolactone | Spironolactone | 52 | 14 |
| Nitroglycerin | Nitroglycerin | 48 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 11 |
| Lovastatin | Lovastatin | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Irbesartan | Irbesartan | 42 | 11 |
| Azithromycin | Azithromycin | 41 | 34 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 21 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 27 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 15 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Glipizide | Glipizide | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Fluconazole | Fluconazole | 23 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Mometasone Furoate | Mometasone Furoate | 19 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Ozempic | Semaglutide | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $339.37 · 19 records | Lilly USA, LLC | CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, INJECTAFER, MOUNJARO, NURTEC ODT, Tyvaso, VRAYLAR, WATCHMAN FLX, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error